Serial #88373373
LIVE

Serial Number

88373373

Owner

PAIGE.AI, Inc.

Attorney

Mark Leonardo

First Use Date

Feb 21, 2019

Filing Date

Apr 5, 2019

Add to watchlist:

No watchlists yet
View on USPTO

Serial #88373373 Trademark

Serial Number: 88373373 • Registration: 6240448

Serial #88373373 is a trademark filed by PAIGE.AI, Inc. on April 5, 2019. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

PAIGE.AI, Inc. (12 trademarks)

New York, NY 10036

Entity Type: 03

Trademark Details

Filing Date

April 5, 2019

Registration Date

January 5, 2021

First Use Anywhere

February 21, 2019

First Use in Commerce

February 21, 2019

Published for Opposition

July 9, 2019

Goods & Services

Medical services; cancer therapy services; medical testing, namely, the review and analysis of patients' clinical slides to identify additional recommended medical testing; medical testing for the diagnosis of diseases, states, or conditions; medical testing for evaluation of prognosis relating to diseases, states, or conditions; medical testing for the monitoring of diseases, states, or conditions; medical testing to detect or identify predispositions to diseases, states, or conditions; medical testing to detect or determine the recurrence of diseases, states, or conditions; medical testing to detect, monitor, or evaluate responses to treatment of diseases, states, or conditions; medical testing to evaluate clinical management of diseases, states, or conditions; medical testing for selection of treatment for diseases, states, or conditions; medical testing to evaluate or facilitate prevention of diseases, states, or conditions; medical testing to select, facilitate, monitor, or evaluate palliation or treatment of diseases, states or conditions; medical testing in the field of cancer; medical testing in the field of oncology; medical diagnostic testing, monitoring, or reporting services; medical analysis or advisory services in the field of cancer; medical analysis or advisory services in the field of oncology; medical analysis or advisory services for medical treatment; medical analysis or advisory services for the diagnosis of diseases, states, or conditions; medical analysis or advisory services for the evaluation of prognosis relating to diseases, states, or conditions; medical analysis or advisory services relating to monitoring diseases, states, or conditions; medical analysis or advisory services relating to the detection or identification of predispositions to diseases, states, or conditions; medical analysis or advisory services relating to the detection or determination of the recurrence of diseases, states, or conditions; medical analysis or advisory services relating to the detection, monitoring, or evaluation of responses to treatment of diseases, states, or conditions; medical analysis or advisory services relating to the clinical management of diseases, states, or conditions; medical analysis or advisory services relating to the selection of treatment for diseases, states, or conditions; medical analysis or advisory services relating to the prevention of diseases, states, or conditions; medical analysis or advisory services relating to the palliation or treatment of diseases, states or conditions; qualitative image analysis in the field of digital pathology for medical purposes; quantitative image analysis in the field of digital pathology for medical purposes; providing non-research related medical information via the internet; medical analysis services for the diagnosis of cancer by reviewing pathological samples on slides

Software as a service (SaaS) services featuring software for artificial intelligence, machine learning, deep learning, statistical learning, data mining, and contextual prediction; software as a service (SaaS) services featuring software for use in disease pathology, namely, software that reads digital slides and provides diagnoses; software as a service (SaaS) services featuring software for use in diagnosis of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in evaluation of prognosis relating to diseases, states, or conditions; software as a service (SaaS) services featuring software for use in monitoring of diseases, states, or conditions; software as a service (SaaS) services featuring software for use to detect or identify predispositions to diseases, states, or conditions; software as a service (SaaS) services featuring software to detect the recurrence of diseases, states, or conditions; software as a service (SaaS) services featuring software to detect, monitor, or evaluate patients' responses to treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in clinical management of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in the selection of treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in prevention of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in palliation or treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in research or development in the field of life sciences; software as a service (SaaS) services featuring software for use in research or development in the field of medicine; software as a service (SaaS) services featuring software for use in research or development in the field of healthcare; software as a service (SaaS) services featuring software for use in research or development in the field of cancer; software as a service (SaaS) services featuring software for use in research or development in the field of oncology; software as a service (SaaS) services featuring software for use in research or development in the field of pathology; design and development of AI-powered computer software that analyzes clinical pathology slides and diagnoses diseases; medical research; scientific research and development services in the field of pathology; research and development services in the field of medicine; research and development services in the field of cancer; research and development services in the field of healthcare; research and development services in the field of life sciences; research and development services in the field of oncology; medical and scientific research services in the field of pathology; medical and scientific research services in the field of cancer; medical and scientific research services in the field of healthcare; medical and scientific research services in the field of life sciences; medical and scientific research services in the field of oncology; research and development of technology in the field of pathology; research and development of technology in the field of medicine; research and development of technology in the field of cancer; research and development of technology in the field of healthcare; research and development of technology in the field of life sciences; research and development of technology in the field of oncology; providing medical research and scientific research information via the internet; electronic scanning of clinical pathology slides; software as a service services (SaaS) featuring software for use in the analysis of clinical pathology slides; medical and scientific testing services for research purposes

Filing History

TEAS SECTION 8 & 15 RECEIVED
Jun 10, 2026 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jan 5, 2026 REM1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 29, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 29, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 29, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 29, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 29, 2021 COAR
REGISTERED-PRINCIPAL REGISTER
Jan 5, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Dec 4, 2020 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Dec 3, 2020 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 24, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 24, 2020 CRFA
ASSIGNED TO LIE
Nov 17, 2020 ALIE
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 13, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 13, 2020 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 13, 2020 COAR
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 13, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 11, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 11, 2020 GNRT
SU - NON-FINAL ACTION - WRITTEN
Sep 11, 2020 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Aug 17, 2020 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 12, 2020 AITU
USE AMENDMENT FILED
Jul 31, 2020 IUAF
TEAS STATEMENT OF USE RECEIVED
Jul 31, 2020 EISU
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 8, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 8, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 8, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 8, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 8, 2020 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 5, 2020 EXRA
SOU EXTENSION 1 GRANTED
Mar 3, 2020 EX1G
SOU EXTENSION 1 FILED
Mar 3, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 3, 2020 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 3, 2019 NOAM
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 14, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 14, 2019 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 9, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jul 9, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 19, 2019 NONP
ASSIGNED TO LIE
May 30, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 15, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
May 15, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 15, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
May 15, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 15, 2019 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
May 8, 2019 GPRN
PRIORITY ACTION E-MAILED
May 8, 2019 GPRA
PRIORITY ACTION WRITTEN
May 8, 2019 CPRA
ASSIGNED TO EXAMINER
May 1, 2019 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Apr 25, 2019 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 23, 2019 NWOS
NEW APPLICATION ENTERED
Apr 9, 2019 NWAP